Targeting Translation Dependence in Cancer

Abba Malina; Regina Cencic; Jerry Pelletier

doi:10.18632/oncotarget.218

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Targeting Translation Dependence in Cancer

Abba Malina, Regina Cencic and Jerry Pelletier _

PDF | HTML | How to cite

Oncotarget. 2011; 2:76-88. https://doi.org/10.18632/oncotarget.218

Metrics: PDF 3293 views | HTML 5398 views | ?

Abstract

Abba Malina¹, Regina Cencic¹, and Jerry Pelletier^1,2

¹Department of Biochemistry, McIntyre Medical Sciences Building, McGill University, Montreal, Quebec, Canada

²The Rosalind and Morris Goodman Cancer Center, McIntyre Medical Sciences Building, McGill University, Montreal, Quebec, Canada

Keywords: Translation, Translational Control, eIF4F, eIF4E, eIF4A, Translation Inhibitor

Received: February 14, 2011; Accepted: February 14, 2011; Published: February 15, 2011;

Correspondence:

Jerry Pelletier, e-mail:

Abstract

A challenge in cancer therapy is to selectively target activities that are essential for survival of malignant cells while sparing normal cells. Translational control represents a potential anti-neoplastic target because it is exerted by major signaling pathways that are often usurped in cancers. Herein we describe approaches being developed that target eukaryotic initiation factor (eIF) 4F, a heterotrimeric complex that integrates multiple signaling inputs to the translation apparatus.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 218

Publication Alerts

Research Perspectives:

Targeting Translation Dependence in Cancer

Abstract